Company news

Oncopeptides AB news in 2026

Oncopeptides AB's news releases, calls and decks from 2026, newest first.

View company

Oncopeptides signs agreement with Salus for distribution and commercialization of Pepaxti in Central and Eastern Europe

May 26, 2026

Oncopeptides (Q1 Update): Strong Quarterly Growth and Decreased Costs

May 20, 2026

Oncopeptides secures regulatory approval to start Window-of-Opportunity study in glioblastoma from Norwegian authorities

May 19, 2026

Oncopeptides publishes Q1 report 2026

May 13, 2026

Oncopeptides intends to submit type II variation to expand Pepaxti label to include third line treatment

May 11, 2026

Invitation to presentation of the Q1 report 2026

May 6, 2026

Oncopeptides publishes the 2025 Annual Report

April 28, 2026

Calls in 2026

Decks in 2026